U.S. Markets close in 1 hr 26 mins

Avadel Pharmaceuticals plc (AVDL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.18-0.27 (-3.20%)
As of 2:31PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.45
Open8.43
Bid8.18 x 800
Ask8.20 x 900
Day's Range8.11 - 8.56
52 Week Range1.82 - 13.49
Volume170,212
Avg. Volume687,526
Market Cap475.495M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th

    DUBLIN, Ireland, July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2020. To access the conference call, investors are invited to dial 877-407-9716 (U.S. and Canada) or 201-493-6779 (international). The conference ID number is 13707645. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.About Avadel Pharmaceuticals plc: Avadel Pharmaceuticals plc (Nasdaq: AVDL) is an emerging biopharmaceutical company. The Company’s primary focus is the development and potential FDA approval of FT218, which has completed a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. For more information, please visit www.avadel.com.Contacts:      Investor Contacts       Tom McHugh       Chief Financial Officer       Phone: (636) 449-1843       Email: tmchugh@avadel.com       Tim McCarthy       LifeSci Advisors, LLC       Phone: (212) 915.2564       Email: tim@lifesciadvisors.com      Media Contact       Patrick Bursey       LifeSci Communications, LLC       Phone: (646) 970-4688       Email: pbursey@lifescicomms.com

  • GlobeNewswire

    Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz®, Vazculep®, and Akovaz®, as well as Nouress™, which is approved by the U.S. Food and Drug Administration, to Exela Sterile Medicines LLC for a total of $42.0 million. “The sale of the sterile injectable drug portfolio is a significant milestone for the Company, as it further reflects our commitment to strategically focus on advancing FT218 through the regulatory review process and, if approved, bringing our once-nightly formulation of sodium oxybate to patients,” said Greg Divis, Chief Executive Officer of Avadel.

  • GlobeNewswire

    Avadel Pharmaceuticals to Present at BIO Digital

    DUBLIN, Ireland, June 08, 2020 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium.